NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...

Shares of Septerna sank to their lowest level yet after the company said it would end the phase 1 clinical trial for SEP-786 as a treatment for hypoparathyroidism. The stock fell 68% to a low of $4.17 ...

The heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for ...

Septerna, a clinical-stage biotechnology company, recently made public its decision to halt the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786, an oral small molecule ...

US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending ...

Fintel reports that on February 18, 2025, Wells Fargo downgraded their outlook for Septerna (NasdaqGM:SEPN) from Overweight ...

Septerna (NASDAQ:SEPN – Get Free Report) was downgraded by equities researchers at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued on Tuesday, ...

Septerna Inc. has announced its decision to discontinue a healthy volunteer phase I trial of SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor being developed for the ...

The decision to halt the trial was made despite the lack of serious adverse events or indications of liver injury, cholestasis, or hemolysis in trial participants. Septerna's CEO, Jeffrey Finer, ...